SCHEMBL8459292

SCHEMBL8459292

CC=CCCCC(=O)CC(=O)CC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 1/20 0.41
FAAH O00519 2/20 0.39
PLA2G4A P47712 1/20 0.38
PPARG P37231 3/20 0.37
TOP1 P11387 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP19A1 P11511 2/20 0.37
KMT2A Q03164 2/20 0.37
PPARD Q03181 2/20 0.37
PPARA Q07869 2/20 0.37
F7 P08709 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
F3 P13726 1/20 0.37
RXRA P19793 1/20 0.37
PTGS1 P23219 1/20 0.37
OXER1 Q8TDS5 1/20 0.37
CNR1 P21554 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8459286 1.00 SOAT1 (0.41) SOAT1FAAHPLA2G4APPARGTOP1
SCHEMBL11974557 0.91 SOAT1 (0.46) SOAT1FAAHPLA2G4APPARGTOP1
SCHEMBL17593582 0.89 FAAH (0.42) SOAT1FAAHPLA2G4APPARGTOP1
SCHEMBL17593583 0.89 FAAH (0.42) SOAT1FAAHPLA2G4APPARGTOP1
SCHEMBL572041 0.87 TDP1 (0.39) SOAT1FAAHPPARGALDH1A1CYP19A1
SCHEMBL572040 0.87 TDP1 (0.39) SOAT1FAAHPPARGALDH1A1CYP19A1
SCHEMBL32675677 0.83 FAAH (0.47) SOAT1FAAHPPARGTOP1CYP19A1
SCHEMBL5050490 0.83 FAAH (0.50) SOAT1FAAHPPARGTOP1CYP19A1
SCHEMBL5050492 0.83 FAAH (0.50) SOAT1FAAHPPARGTOP1CYP19A1
SCHEMBL2907806 0.82 FAAH (0.55) SOAT1FAAHPPARGTOP1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-5961483-A Iontophoretic delivery of cell adhesion inhibitors COLLATERAL AGENTS, LLC 1999-10-05 US disclosed
US-5935598-A DEVICE FOR NON-INVASIVE ADMINISTRATION OF A CELL ADHESION RECEPTOR ANTAGONIST TO A MAMMAL; CURRENT DISTRIBUTING MEMBER, IONIZABLE ANTAGONIST RESERVOIR, ELECTROLYTE RESERVOIR, POWDER SOURCE; TREATING THROMBOSIS, ANTICOAGULANTS BECTON DICKINSON RESEARCH CENTER (US) 1999-08-10 US disclosed
US-5849736-A Isoxazoline and isoxazole fibrinogen receptor antagonists THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A SOAT1 3602/4885FAAH 3670/4885PLA2G4A 4733/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A SOAT1 3602/4885FAAH 3670/4885PLA2G4A 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.